Vogenx, Inc. (VOGX)
Nasdaq · Healthcare · Biotechnology
$17.15−5.92%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $255M
- 52-week range
- $12.95 – $38.41
- 52-week change
- +40.23%
- EPS (trailing)
- −$0.22
- Analyst rating
- 1.0 Strong buy
About Vogenx, Inc.
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Headquarters: Raleigh, United States · 4 employees · vogenx.com